Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2018 2
2020 1
2021 1
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
A β-Catenin-TCF-Sensitive Locus Control Region Mediates GUCY2C Ligand Loss in Colorectal Cancer.
Rappaport JA, Entezari AA, Caspi A, Caksa S, Jhaveri AV, Stanek TJ, Ertel A, Kupper J, Fortina PM, McMahon SB, Jaynes JB, Snook AE, Waldman SA. Rappaport JA, et al. Among authors: fortina pm. Cell Mol Gastroenterol Hepatol. 2022;13(4):1276-1296. doi: 10.1016/j.jcmgh.2021.12.014. Epub 2021 Dec 22. Cell Mol Gastroenterol Hepatol. 2022. PMID: 34954189 Free PMC article.
MicroRNA-139 Expression Is Dispensable for the Generation of Influenza-Specific CD8+ T Cell Responses.
Hope JL, Zhao M, Stairiker CJ, Kiernan CH, Carey AJ, Mueller YM, van Meurs M, Brouwers-Haspels I, Otero DC, Bae EA, Faso HA, Maas A, de Looper H, Fortina PM, Rigoutsos I, Bradley LM, Erkeland SJ, Katsikis PD. Hope JL, et al. Among authors: fortina pm. J Immunol. 2022 Feb 1;208(3):603-617. doi: 10.4049/jimmunol.2000621. Epub 2022 Jan 12. J Immunol. 2022. PMID: 35022277 Free PMC article.
In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.
Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE. Teh JLF, et al. Among authors: fortina pm. Cancer Discov. 2018 May;8(5):568-581. doi: 10.1158/2159-8290.CD-17-0699. Epub 2018 Mar 1. Cancer Discov. 2018. PMID: 29496664 Free PMC article.
Correction: In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.
Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE. Teh JLF, et al. Among authors: fortina pm. Cancer Discov. 2018 Dec;8(12):1654. doi: 10.1158/2159-8290.CD-18-1291. Cancer Discov. 2018. PMID: 30510016 No abstract available.